PREA and BPCA: Spurring Pediatric Drug Development

The Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA), permanently reauthorized in 2012, work together to foster pediatric drug development, creating a balanced approach that generates important safety and efficacy information on use of medicines in children and enables biopharmaceutical companies to continue to make significant investments in pediatric drug research. 

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.